NDA 208434 · Hoffmann-La Roche
Alecensa
Alectinib Hydrochloride · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 11, 2015
Approved uses
4
Original approval plus efficacy supplements
Registered trials
77
14 Phase 3, 20 recruiting
FAERS reports
7,388
4,065 serious, 951 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 21, 2026.
ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive) as detected by an FDA-approved test. ( 1.1 ) treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. ( 1.2 ) 1.1 Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC) ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test [see Dosage & Administration (2.1) ]. 1.2 Treatment of Metastatic ALK-Positive NSCLC ALECENSA is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test [see Dosage & Administration (2.1) ] .
Mechanism: Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity. Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 11, 2026 Supplement 16 · Efficacy OrphanLetterLabel
- Apr 18, 2024 Supplement 15 · Efficacy · priority review OrphanLetterReviewLabel
- Nov 6, 2017 Supplement 3 · Efficacy · priority review Breakthrough therapyLabelLetter
- Dec 11, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanReviewSummary ReviewLabel
1 products under this application
- ALECENSA · ALECTINIB HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alectinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03768063 · 1,000 participants (planned) · Start Feb 28, 2019 · Primary completion Jul 5, 2028
Drug: Atezolizumab; Bevacizumab and 14 more · For: Cancer
Sites: Aurora, Colorado; Trumbull, Connecticut; Boston, Massachusetts · 80 sites in all
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03178552 · 1,000 participants (planned) · Start Sep 22, 2017 · Primary completion Jun 30, 2027
Drug: Alectinib; Atezolizumab and 10 more · For: Non-Small Cell Lung Cancer
Sites: Sacramento, California; Denver, Colorado; Fort Myers, Florida · 161 sites in all
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolPivotal-lookingRecruiting
Cancer Research UKAcademic, hospital or other
NCT05722886 · 825 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 2029
Drug: Alectinib; Atezolizumab and 5 more · For: Haematological Malignancy; Solid Tumour
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death718
- fatigue526
- no adverse event472
- off label use472
- constipation455
- rash267
- dyspnoea240
- disease progression216
- weight increased213
- myalgia212
- asthenia200
- peripheral swelling180
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 125 |
| 2017 | 255 |
| 2018 | 529 |
| 2019 | 589 |
| 2020 | 878 |
| 2021 | 704 |
| 2022 | 759 |
| 2023 | 743 |
| 2024 | 1,856 |
| 2025 | 541 |
| 2026 | 409 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Alecensa (Alectinib HCl)
2024 spending
$247M
Beneficiaries
1,906
14,597 claims
Per beneficiary
$129,435
$76.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $105,142,346 |
| 2021 | $125,219,804 |
| 2022 | $153,932,232 |
| 2023 | $185,955,638 |
| 2024 | $246,703,794 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T, Camidge DR, Gadgeel SM, et al. · Ann Oncol 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.
Peters S, Camidge R, Dziadziuszko R, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
Ou SH, Kilvert H, Candlish J, et al. · Lung Cancer 2024 · Systematic Review, Comparative Study
- Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.
Garcia C, Abrahami D, Polli A, et al. · Clin Lung Cancer 2024 · Comparative Study, Clinical Trial, Phase III
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.